Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.90 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254947 | 1.00 | ABCG2 (0.90) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL15631510 | 0.90 | ABCG2 (0.91) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL25198837 | 0.90 | ABCG2 (0.83) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL25237374 | 0.90 | ABCG2 (0.83) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL20339099 | 0.89 | ABCG2 (0.88) | ABCG2MAPTMEN1KMT2ABCHE | |
| SCHEMBL20339098 | 0.89 | ABCG2 (0.88) | ABCG2MAPTMEN1KMT2ABCHE | |
| SCHEMBL6936004 | 0.88 | ABCG2 (0.80) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL6936000 | 0.88 | ABCG2 (0.80) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL15807361 | 0.86 | MAPT (0.75) | ABCG2MAPTMEN1NPC1RAB9A | |
| SCHEMBL1319394 | 0.86 | ABCG2 (0.83) | ABCG2MAPTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130724-A1 | Enzymatic Demethylation of Flavonoids | UNIVERSITEIT GENT (BE) | 2009-05-21 | — | — | US | claimed |
| EP-1869200-B1 | ENZYMATIC DEMETHYLATION OF FLAVONOIDS | UNIV GENT (BE) | 2008-09-03 | — | — | EP | claimed |
| EP-1869200-A1 | ENZYMATIC DEMETHYLATION OF FLAVONOIDS | UNIVERSITEIT GENT (BE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006099699-A1 | ENZYMATIC DEMETHYLATION OF FLAVONOIDS | UNIVERSITEIT GENT (BE) | 2006-09-28 | — | — | WO | claimed |
| US-20240298520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-09-05 | — | — | US | disclosed |
| EP-3437640-B1 | AGENT FOR TREATING SYNUCLEINOPATHY | UNIV TOHOKU (JP) | 2021-11-24 | — | — | EP | disclosed |
| EP-3437640-B1 | AGENT FOR TREATING SYNUCLEINOPATHY | UNIV TOHOKU (JP) | 2021-11-24 | — | — | EP | disclosed |
| CN-113461501-A | Green method for high-selectivity synthesis of chalcone compounds | 温州大学 | 2021-10-01 | — | — | CN | disclosed |
| US-10737995-B2 | Nuclear receptor modulators and their use for the treatment and prevention of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-08-11 | — | — | US | disclosed |
| US-10709688-B2 | Agent for treating synucleinopathy | TOHOKU UNIVERSITY (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10709688-B2 | Agent for treating synucleinopathy | TOHOKU UNIVERSITY (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | TOHOKU UNIVERSITY (JP) | 2019-05-02 | — | — | US | disclosed |
| US-8709764-B2 | Enzymatic demethylation of flavonoids | UNIVERSITEIT GENT (BE) | 2014-04-29 | — | — | US | disclosed |
| US-20140088052-A1 | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012174436-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012116362-A2 | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20090130724-A1 | Enzymatic Demethylation of Flavonoids | UNIVERSITEIT GENT (BE) | 2009-05-21 | — | — | US | disclosed |
| EP-1869200-B1 | ENZYMATIC DEMETHYLATION OF FLAVONOIDS | UNIV GENT (BE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1869200-A1 | ENZYMATIC DEMETHYLATION OF FLAVONOIDS | UNIVERSITEIT GENT (BE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006099699-A1 | ENZYMATIC DEMETHYLATION OF FLAVONOIDS | UNIVERSITEIT GENT (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709688-B2 | Agent for treating synucleinopathy | SNCA, PARK7, SYNJ1 | ABCG2 3730/4885MAPT 10/4885MEN1 3785/4885 |
| US-20190125726-A1 | AGENT FOR TREATING SYNUCLEINOPATHY | SNCA, PARK7, SYNJ1 | ABCG2 3730/4885MAPT 10/4885MEN1 3785/4885 |
| US-10737995-B2 | Nuclear receptor modulators and their use for the treatment and prevention of cancer | AR, NCOA1, NR5A1 | ABCG2 742/4885MAPT 4183/4885MEN1 2036/4885 |
| US-20140088052-A1 | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS | NFE2L2, NFE2, KEAP1 | ABCG2 3815/4885MAPT 3465/4885MEN1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.